/third-meeting-of-the-intergovernmental-working-group-on-the-who-pandemic-agreement.tmb-1200v.jpg?sfvrsn=b400bf69_6 "WHO PABS Negotiations: Progress Towards Pandemic Agreement Annex")
WHO PABS Negotiations: Progress Towards Pandemic Agreement Annex
The world is continuing to build on the momentum of a landmark agreement designed to safeguard global health security. Member States of the World Health Organization (WHO) recently concluded a week of intensive negotiations focused on a crucial annex to the WHO Pandemic Agreement: the Pathogen Access and Benefit Sharing (PABS) system. These discussions, held from February 9-14, 2026, represent a significant step toward ensuring a more equitable and effective response to future pandemics.
The Imperative of Rapid Sharing
The COVID-19 pandemic starkly revealed the critical need for swift pathogen surveillance and data sharing. To effectively counter emerging threats, countries must be able to quickly identify pathogens with pandemic potential and openly exchange their genetic information and biological materials. This rapid action is essential for accelerating the development of vital tools – diagnostics, treatments and vaccines – that can mitigate the impact of outbreaks. The PABS system is specifically designed to facilitate this timely sharing, grounded in principles of equity and mutual benefit. It aims to ensure that access to pathogen materials and data is based on public health needs, and that the benefits derived from these resources are shared fairly among nations.
As Dr. Tedros Adhanom Ghebreyesus, WHO Director-General, stated following the adoption of the Pandemic Agreement last year, “Strong multilateralism remains essential as countries have to face future pandemics together, collectively.” This sentiment underscores the collaborative spirit driving the PABS negotiations.
Navigating Complexities in the PABS System
The negotiations, as described by Ambassador Tovar da Silva Nunes of Brazil, a co-chair of the Intergovernmental Working Group (IGWG), focused on streamlining the text of the annex even as addressing more challenging areas through further consultation. The IGWG, established by the World Health Assembly (WHA) last year, is tasked with finalizing the PABS annex, which will then be presented to the WHA for approval in May.
Mr. Matthew Harpur, of the United Kingdom, the other IGWG Bureau co-chair, acknowledged that “essential differences remain” but emphasized a “shared recognition of what is at stake.” With the May deadline approaching, the coming weeks will be crucial for bridging these gaps and delivering a PABS annex that is considered fair, effective, and fit for purpose.
What Does ‘Benefit Sharing’ Actually Mean?
The concept of “benefit sharing” within the PABS system extends beyond simply providing access to vaccines or treatments. It encompasses a range of potential benefits, including intellectual property rights, financial gains, and the development of local manufacturing capacity. The goal is to create a system where countries that contribute pathogen materials or data also benefit from any resulting innovations. This is particularly important for low- and middle-income countries, which may lack the resources to independently develop these tools.
The WHO’s Pandemic Agreement, adopted in May 2025, serves as the foundation for this work. It aims to correct the global weaknesses exposed by the COVID-19 pandemic and strengthen international coordination. The agreement is legally binding and designed to make the world safer and more equitable in the face of future health emergencies.
Stakeholder Engagement: A Multi-Sector Approach
Recognizing the complexity of pandemic preparedness and response, Member States engaged with a diverse range of stakeholders during the negotiations. This included representatives from the private sector, academic institutions, laboratories, and sequence information databases. This broad engagement is intended to ensure that the PABS system is practical, sustainable, and reflects the needs of all relevant actors.
The importance of collaboration with the private sector is particularly noteworthy. Pharmaceutical companies and biotechnology firms play a crucial role in developing and manufacturing pandemic countermeasures. Ensuring their participation in the PABS system is essential for accelerating innovation and ensuring equitable access to these tools.
Looking Ahead: The Path to Implementation
The next month will be critical as Member States work to finalize the PABS annex in time for the May WHA meeting. Key areas of focus will likely include clarifying the scope of pathogen materials and data covered by the system, establishing clear mechanisms for benefit sharing, and addressing concerns about intellectual property rights.
The successful implementation of the PABS system will require ongoing commitment and collaboration from all stakeholders. It will also necessitate the development of robust monitoring and evaluation mechanisms to ensure that the system is functioning effectively and achieving its goals. The challenges are significant, but the potential benefits – a more equitable and effective global response to future pandemics – are immense.
Following the adoption of the annex, the next step will be its formal ratification by countries, a process that will vary depending on national constitutional procedures. The WHO Pandemic Agreement will officially come into force 30 days after 60 countries have ratified it, marking a fresh era of global health security.